跳至主要内容
临床试验/EUCTR2005-005939-10-FI
EUCTR2005-005939-10-FI进行中(未招募)不适用

A study in healthy, young adults and healthy infants of the safety, tolerability, and immunogenicity of an investigational manufacturing process for the recombinant hepatitis B vaccine - Assessment of GSH/2X Phosphate Hepatitis B Vaccine.

Merck & Co. Inc.0 个研究点目标入组 300 人开始时间: 2006年3月21日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • a. Twenty to 35 years of age.
  • b. In general good health based on a medical history taken on Day 1 prior to receiving the first injection of vaccine. Any underlying chronic illness must be documented to be in stable condition.
  • c. For women, a negative urine pregnancy test just prior to vaccination on Day 1.
  • d. Women of childbearing potential must demonstrate a method of effective contraception. Effective contraception includes the birth control pill or abstinence during the entire study period.
  • a. Healthy infants.
  • b. Two to 4 months old.
  • c. Available for the study period.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years)
  • F.1.3.1 Number of subjects for this age range

排除标准

  • a. Medical History of previous hepatitis B infection. This includes the mothers of subjects in Stage 2.
  • b. Medical History of vaccination with any other hepatitis B vaccine. This includes the mothers of subjects in Stage 2.
  • c. Medical History of injection drug use.
  • d. Recent (<72 hours) history of febrile illness (oral temperature =37.8ºC/=100.0ºF; rectal temperature =38.1ºC/=100.5ºF ).
  • e. Known or suspected hypersensitivity to any component of RECOMBIVAX HB vaccine (e.g., aluminum, yeast).
  • f. Recent administration (within 3 months prior to first injection with the study vaccine) of any of the following or if any of the following are scheduled to be given during the study: hepatitis B immune globulin (HBIG), serum immune globulin, or any other blood-derived product (excluding autologous products).
  • g. Receipt of investigational drugs or other investigational vaccines within 3 months prior to first injection with the study vaccine or if scheduled to be given during the study.
  • h. Known or suspected impairment of immunologic function or recent use (defined as 3 months prior to study start) of immunomodulatory medications (e.g., systemic corticosteroids). Does not include topical and inhaled steroids.
  • i. Pregnant women, nursing mothers, and women planning to become pregnant within the study period.
  • j. Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
  • k. Inability to comply with the study schedule and attend all required study visits as outlined in the Study Flow Chart.

研究者

相似试验

A study in healthy, young adults and healthy infants... | 临床试验